Late Breaking Abstract - Management of asthma in pregnancy using fractional exhaled nitric oxide (FENO) to adjust inhaled corticosteroid (ICS) dose did not improve perinatal outcomes: the Breathing for Life Trial (BLT)

V. Murphy (Callaghan, Australia), M. Jensen (Callaghan, Australia), E. Holliday (Callaghan, Australia), W. Giles (Sydney, Australia), H. Barrett (Brisbane, Australia), L. Callaway (Brisbane, Australia), A. Bisits (Sydney, Australia), M. Peek (Canberra, Australia), S. Seeho (Sydney, Australia), A. Abbott (Sydney, Australia), P. Colditz (Brisbane, Australia), A. Searles (Newcastle, Australia), J. Attia (Newcastle, Australia), M. Hensley (Newcastle, Australia), J. Mattes (Newcastle, Australia), P. Gibson (Newcastle, Australia)

Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers

Session: Lung function tests and exhaled biomarkers
Session type: E-poster session
Number: 138

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Murphy (Callaghan, Australia), M. Jensen (Callaghan, Australia), E. Holliday (Callaghan, Australia), W. Giles (Sydney, Australia), H. Barrett (Brisbane, Australia), L. Callaway (Brisbane, Australia), A. Bisits (Sydney, Australia), M. Peek (Canberra, Australia), S. Seeho (Sydney, Australia), A. Abbott (Sydney, Australia), P. Colditz (Brisbane, Australia), A. Searles (Newcastle, Australia), J. Attia (Newcastle, Australia), M. Hensley (Newcastle, Australia), J. Mattes (Newcastle, Australia), P. Gibson (Newcastle, Australia). Late Breaking Abstract - Management of asthma in pregnancy using fractional exhaled nitric oxide (FENO) to adjust inhaled corticosteroid (ICS) dose did not improve perinatal outcomes: the Breathing for Life Trial (BLT). 138

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016
Cost savings using fractional exhaled nitric oxide (FeNO) testing in asthma management by specialists Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013
Non-adherence to inhaled corticosteroid therapy as an explanation for persistently elevated exhaled nitric oxide levels in patients with asthma: Effect of directly observed therapy with inhaled corticosteroids (DOT-ICS) Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI). Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Domiciliary diurnal variation of fractional exhaled nitric oxide (FeNO) for predicting short-term treatment effect Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016
The experience of monitoring the exhaled nitric oxide (FeNO) during the anti-IgE-therapy (omalizumab) in children with uncontrolled severe asthma Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Optimising inhaled corticosteroid (ICS) dose using exhaled nitric oxide (eNO) measurements Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes? Source: International Congress 2018 – Clinical and functional monitoring in airway disease Year: 2018
Concomitant use of fractional exhaled nitric oxide (FeNO) and asthma control test (ACT) as markers for predicting asthma exacerbation Source: International Congress 2014 – Asthma: clinical problems Year: 2014
Interaction between airway calibre and exhaled NO: Impact on asthma control assessment Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013
Domiciliary diurnal variation of fractional exhaled nitric oxide (FeNO) to monitor asthma control Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013
Dynamics of the nitric oxide metabolites in the exhaled breath condensate (EBC) in atopic asthma (BA) children receiving various treatment options Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013
Economic evaluation of fractional exhaled nitric oxide (FENO) for the management of adult asthma in Spain Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease Year: 2015
Further evidence that FeNO directed therapy reduces asthma exacerbations Source: International Congress 2014 – Airway biomarkers Year: 2014
Exhaled nitric oxide (FeNO) levels to guide treatment for adults with asthma: A Cochrane systematic review Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016
A study of exhaled NO (FENO) measurement used to determine asthma control, dose of inhaled corticosteroid and cost in a developing country Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015
Exhaled nitric oxide and the therapeutic regimens in childhood asthma Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013
Normal values of exhaled nitric oxide at 50 mL/s – A revisit Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014
Meta analysis of asthma exacerbation rates in adult and pediatric asthmatics managed using fractional exhaled nitric oxide versus standard clinical parameters alone Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013